All the news Showing 10 of 40 articles from: EASL 2016Get an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Interferon-free regimens Sofosbuvir/velpatasvir + GS-9857 works well for treatment-experienced hepatitis C patients Liz Highleyman / 15 April 2016 A triple combination of Gilead Sciences' sofosbuvir, velpatasvir and GS-9857 demonstrated a high sustained response rate for treatment-experienced people with all hepatitis C virus (HCV) genotypes who previously were not cured with prior ... Treatment in cirrhosis Hepatitis C treatment may not be enough to stop the progress of advanced liver disease, or reduce liver transplant need Keith Alcorn / 14 April 2016 Doctors need to have “full and frank” discussions with patients about the potential risks and benefits of using direct-acting antivirals to treat hepatitis C in late-stage liver disease, especially among those waiting for ... Treatment outcomes One year after universal HCV treatment, Portugal shows 96% SVR rate Healio Hepatology / 14 April 2016 Liver transplants Hepatitis C infected livers offer similar outcomes to healthy livers in those waiting for liver transplants EASL press release / 14 April 2016 Testing for hepatitis C Research shows doctors are failing to diagnose more than 50% of patients with hepatitis C virus (HCV) World Hepatitis Alliance / 14 April 2016 Access to medicines & diagnostics $300 hepatitis C combination to enter clinical trials Keith Alcorn / 13 April 2016 The Drugs for Neglected Diseases Initiative (DNDI) is launching clinical trials in Thailand and Malaysia to test a combination of sofosbuvir and ravidasvir, an NS5A inhibitor, in at least 800 people with ... Transmission, epidemiology and prevention Combined HIV and hepatitis C virus vaccination a possibility EASL press release / 13 April 2016 Models of care Community-based treatment providers can help ease pressure on specialists in battle against hep C EASL press release / 13 April 2016 Treatment for people living with HIV and HCV Differing perspectives on antiviral treatment efficacy in patients co-infected with HIV and HCV EASL press release / 13 April 2016 Health services, policy and advocacy Elimination of viral hepatitis by 2030 is now the goal, advocates say Keith Alcorn / 12 April 2016 Hepatitis advocates are to launch a push for a global campaign to eliminate viral hepatitis by 2030. The move is part of a drive to raise political commitment for tackling viral hepatitis. The ... ← Prev1234Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive